Clinical trials: completed, in Mongolia
Skin Inflammation, Cosmetic Skin
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.
- Trial name
- NCT06387212
- Testing
- 35 kDa hyaluronan fragment HA35 injection
- Where
- Mongolia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nakhia Impex LLC
Chronic Wound, Myofascial Pain Syndrome
Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome
To verify the efficacy and safety of HA35 in chronic pain management and to further supplement effective treatments for chronic pain, we designed a proof-of-concept clinical study.
- Trial name
- NCT06444035
- Testing
- HA35 injection
- Where
- Mongolia
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Chronic Hepatitis D Infection
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
- Trial name
- NCT05827146
- Testing
- Hepalatide
- Where
- 3 sites in China, Mongolia
- Volunteers
- 23 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Advanced Lung Cancer
A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer
In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.
- Trial name
- NCT05852002
- Testing
- 35 kDa hyaluronan fragment
- Where
- Mongolia
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Hepatitis Delta Virus
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral…
- Trial name
- D-LIVR (NCT03719313)
- Testing
- Lonafarnib, Ritonavir, PEG IFN-alfa-2a
- Where
- 116 sites in United States, Belgium and 20 more
- Volunteers
- 407 people
- Sponsor
- Eiger BioPharmaceuticals
Tuberculosis
TB Immunotherapy Trial With Heat-killed M. Vaccae
The purpose of the study is to carry out multi-country (Ukraine and Mongolia), placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug resistant (MDR-TB) and TB-HIV and identify efficacy and…
- Trial name
- imm03 (NCT01977768)
- Testing
- V7
- Where
- 2 sites in Mongolia, Ukraine
- Volunteers
- 152 people
- Sponsor
- Immunitor LLC